Modelling time-kill studies to discern the pharmacodynamics of meropenem.
about
A novel approach to pharmacodynamic assessment of antimicrobial agents: new insights to dosing regimen designElucidation of the Mode of Action of a New Antibacterial Compound Active against Staphylococcus aureus and Pseudomonas aeruginosaSemimechanistic pharmacokinetic-pharmacodynamic model with adaptation development for time-kill experiments of ciprofloxacin against Pseudomonas aeruginosa.Mathematical model to quantify the effects of risk factors on carbapenem-resistant Acinetobacter baumannii.Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosaMathematical modeling to characterize the inoculum effect.Predicting in vitro antibacterial efficacy across experimental designs with a semimechanistic pharmacokinetic-pharmacodynamic model.Quantitative impact of neutrophils on bacterial clearance in a murine pneumonia modelIn vitro pharmacodynamics of various antibiotics in combination against extensively drug-resistant Klebsiella pneumoniae.Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments.Multiple Genetic Mutations Associated with Polymyxin Resistance in Acinetobacter baumanniiA multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitro.In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures.Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development.In Vitro Activity of Polymyxin B in Combination with Various Antibiotics against Extensively Drug-Resistant Enterobacter cloacae with Decreased Susceptibility to Polymyxin B.A simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria.Evaluating Polymyxin B-Based Combinations against Carbapenem-Resistant Escherichia coli in Time-Kill Studies and in a Hollow-Fiber Infection Model.Pharmacological considerations for the proper clinical use of aminoglycosides.Translational Pharmacometric Evaluation of Typical Antibiotic Broad-Spectrum Combination Therapies Against Staphylococcus Aureus Exploiting In Vitro InformationTranslational PK/PD of anti-infective therapeutics.Antimicrobial activity of Nigerian medicinal plants.Commercial Essential Oils as Potential Antimicrobials to Treat Skin Diseases.A pharmacokinetic-pharmacodynamic model characterizing the emergence of resistant Escherichia coli subpopulations during ertapenem exposure.Evaluation of toxic effects of several carboxylic acids on bacterial growth by toxicodynamic modelling.Relationship between pharmacodynamic indices and killing patterns in vitro.Bactericidal Effect of Pterostilbene Alone and in Combination with Gentamicin against Human Pathogenic Bacteria.Dynamic interaction of colistin and meropenem on a WT and a resistant strain of Pseudomonas aeruginosa as quantified in a PK/PD model.Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percent for a static effect in vivo.Comparative pharmacodynamics of gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa.In Vitro Activity of Retapamulin against Staphylococcus aureus Resistant to Various Antimicrobial Agents.Pharmacokinetic-pharmacodynamic modeling of the in vitro activities of oxazolidinone antimicrobial agents against methicillin-resistant Staphylococcus aureus.In vitro and in vivo anticandidal activities of alginate-enclosed chitosan-calcium phosphate-loaded Fe-bovine lactoferrin nanocapsules.Can a pharmacokinetic/pharmacodynamic (PKPD) model be predictive across bacterial densities and strains? External evaluation of a PKPD model describing longitudinal in vitro data.Exploration of optimal dosing regimens of vancomycin in patients infected with methicillin-resistant Staphylococcus aureus by modeling and simulation.A general model-based design of experiments approach to achieve practical identifiability of pharmacokinetic and pharmacodynamic models.Mathematical modelling of the antibiotic-induced morphological transition of Pseudomonas aeruginosa.Modelling of ciprofloxacin killing enhanced by hyperbaric oxygen treatment in Pseudomonas aeruginosa PAO1 biofilms.In vitro antibacterial and time-kill evaluation of phosphanegold(I) dithiocarbamates, R3PAu[S2CN(iPr)CH2CH2OH] for R = Ph, Cy and Et, against a broad range of Gram-positive and Gram-negative bacteria
P2860
Q28476705-961168D5-C3D8-48C3-AA24-A0EB75B0ED55Q28551971-0905206E-9BB6-4417-B8FD-50451E2D65E1Q33876563-0F90F243-FAAE-47A7-B82B-71E16686A6CEQ34057420-DF182978-ABB6-40EF-9C92-0BF7F6DD3B2FQ34228382-F08DEEFF-9067-4677-9C15-B0F415D74CEAQ34290045-9004CB16-433E-4D12-A0F0-8C2DD6C85BE5Q34737629-7E3C5471-EC8F-4D53-9EDC-B4AD7AE87E82Q35270290-DCB3ACE4-4CBB-4183-9EE6-AB18EB36EA28Q35385713-7F8D2255-952A-48A3-90B8-0DE6D02AC070Q35635652-E0FEE9A1-A549-4899-9D35-2A867FEB632DQ36290637-CD5FC05C-AEDD-4909-8955-8A37D9DBF750Q36684146-FF35CB51-D3E7-4890-BE9D-6D55CCC5B401Q36744871-31C74AB6-A584-4C80-8BEA-156D8AEA57B6Q36949430-92648F53-2374-4574-AC3C-4C0CA087FCC7Q37203872-EEE6027B-D59D-424E-9DBA-9FFE9621EA92Q37441394-F75DC5EF-6446-4361-8922-654E3E391EEBQ37538693-4AE30BEB-29DB-4E3D-92C2-96467E505400Q37956403-D9AAD209-C878-4DAD-881E-C67188B2EF8EQ38853629-3DF22842-1D23-4FE7-AE1E-259CC59A1738Q39039505-7FC59019-C5E1-4507-B9DB-3AB84A0EFFAAQ39312327-0860D409-99C9-4E63-A9AC-586D2E71D60CQ39331661-03072736-3144-4331-9843-0EF7C04A9DC4Q39665401-EBB04CC1-DD56-4396-9E69-FF54E3CB4FE8Q39714360-B9387DA9-E71F-4436-B954-55A5E9243F03Q39735382-DAC7DE8F-4C21-4D5A-9A07-E5281699CA32Q40290158-CFA54B27-DDEC-408B-B832-4EC8845DEFE7Q40802708-2D38DAFF-16C7-4F0F-A6DC-08FC8C95BBE9Q41879559-79193263-0FAE-44E6-A456-66C941700115Q42549535-D8CD3ED8-B057-4E0E-966C-6EE836D61580Q42572976-72B88DF3-5826-4A8F-9C77-99006F978BC4Q42687502-EC3C4FE3-1994-45BF-9288-F2AADDEC4811Q47706009-D1DF2EBD-95D6-4DDA-8246-CF847D26EE5EQ47897914-C2E194E8-DF21-493D-9723-4557550DEB1FQ51123254-A3E864A5-42D9-4BEA-992A-4BCCED773F23Q51208291-2279BA89-1C8F-4182-9916-A0260E5D1955Q51738032-9188F46E-D092-4687-B086-D194002FC3DFQ55317638-E0ADEB59-0A50-4144-8387-973BE636229EQ59319251-AEF5DB2B-D247-4B1E-AF91-6604188AEE17
P2860
Modelling time-kill studies to discern the pharmacodynamics of meropenem.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Modelling time-kill studies to discern the pharmacodynamics of meropenem.
@en
Modelling time-kill studies to discern the pharmacodynamics of meropenem.
@nl
type
label
Modelling time-kill studies to discern the pharmacodynamics of meropenem.
@en
Modelling time-kill studies to discern the pharmacodynamics of meropenem.
@nl
prefLabel
Modelling time-kill studies to discern the pharmacodynamics of meropenem.
@en
Modelling time-kill studies to discern the pharmacodynamics of meropenem.
@nl
P2093
P2860
P356
P1476
Modelling time-kill studies to discern the pharmacodynamics of meropenem.
@en
P2093
Amy N Schilling
Michael Nikolaou
Vincent H Tam
P2860
P304
P356
10.1093/JAC/DKI086
P407
P577
2005-03-16T00:00:00Z